Active, not recruitingPHASE1, PHASE2NCT04068194
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Studying Cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Kristen R SpencerLaura and Isaac Perlmutter Cancer Center at NYU
- Intervention
- Avelumab(drug)
- Enrollment
- 103 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2027
Study locations (30)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- UCHealth University of Colorado Hospital, Aurora, Colorado, United States
- Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut, United States
- Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury, Connecticut, United States
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich, Connecticut, United States
- Smilow Cancer Hospital Care Center - Guilford, Guilford, Connecticut, United States
- Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
- Yale University, New Haven, Connecticut, United States
- Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04068194 on ClinicalTrials.govOther trials for Cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07478523FAPI-PET Value for the Initial Screening of Pancreatic and Biliary CancersUniversity Hospital, Bordeaux
- RECRUITINGNANCT07476651Scout Dose of Resin MicrospheresSeoul National University Hospital
- RECRUITINGPHASE2NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce
- RECRUITINGPHASE2NCT07201519Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyMichael J Cavnar, MD
- RECRUITINGPHASE2NCT07223307REGULUS: MRI-guided Adaptive SABR for Liver CancersStanford University
- RECRUITINGPHASE2NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGNANCT06735560Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NENNantes University Hospital
- RECRUITINGNCT07206355In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary CancersUniversity of Nottingham